New therapies for relapsed or refractory aggressive B‐cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group

Documenti analoghi

• New therapies for relapsed or refractory aggressive B‐cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group
  di: Mariana Bastos‐Oreiro, et al.
  Pubblicazione: (2024-04-01)
• Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study
  di: Leyre Bento, et al.
  Pubblicazione: (2025-07-01)
• Chimeric antigen receptor T‐cell therapy outcomes in T cell/histiocyte‐rich large B‐cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study
  di: Mariana Bastos‐Oreiro, et al.
  Pubblicazione: (2025-02-01)
• Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study
  di: Alejandro Martín García-Sancho, et al.
  Pubblicazione: (2022-03-01)
• Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO)
  di: Francisco-Javier Peñalver, et al.
  Pubblicazione: (2017-02-01)